SNDX vs SYRE Stock Comparison

SYRE currently leads SNDX in this stock comparison, with AIQ scores of 64 vs 43. The clearest difference is momentum, while SNDX has the stronger value profile.

Market data as of Nov 15, 2026 market close· AIQ score gap 21 points
SNDX
Healthcare
vs
SYRE
Healthcare
SNDX
Syndax Pharmaceuticals, Inc.
Price
$9.45
Day move
-0.94%
AIQ Score
43/100
Best edge
Value
Sector
Healthcare
SYRE
Spyre Therapeutics, Inc.
Leads
Price
$104
Day move
+1.06%
AIQ Score
64/100
Best edge
Momentum
Sector
Healthcare

What is the main difference between SNDX and SYRE?

SYRE leads the current stock comparison as Spyre Therapeutics, Inc., with the clearest separation coming from momentum and the broader AIQ evidence mix.

AlgovestIQ AIQ Comparison

Syndax Pharmaceuticals, Inc. vs Spyre Therapeutics, Inc.

Data as of Nov 15, 2026· market close· Healthcare· Coverage 64/66 fields· High confidence
AIQ VerdictCompetitiveAIQ Comparison Conviction 7/10

SYRE leads

SYRE leads by 21 AIQ points, primarily on Momentum and Risk Resilience, and the lead has widened from 14 points over 30 sessions. Wall Street currently favors SNDX on target upside.

Competitive: 3 of 6 evidence groups support SYRE, its lead is widening, and its current signal state is conflicted.

Evidence agreement: 3 of 6Comparison trend: Strengthening
SNDX

Syndax Pharmaceuticals, Inc.

AIQ Score
43/100
AIQ Edge Score
2/10
SYRE

Spyre Therapeutics, Inc.

Leads
AIQ Score
64/100
AIQ Edge Score
7/10

The Algovestiq AIQ Score currently favors SYRE over SNDX, 64 versus 43 as of Nov 15, 2026. SYRE's advantage is driven primarily by stronger momentum and risk resilience, while SNDX holds the stronger value profile. SYRE also shows the stronger technical structure relative to its 50-day moving average, though analyst target upside currently favors SNDX. 3 of 6 covered evidence groups favor SYRE today, and the comparison is rated Competitive on stability: only 3 of 6 covered evidence groups agree. SYRE lead: Strengthening — the AIQ differential moved from 14 to 21 points over 30 sessions.

Compare Syndax Pharmaceuticals, Inc. and Spyre Therapeutics, Inc. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.

Currently unavailable

Performance over time

Price return from daily closes; distributions are not included.

SNDX
-39.7%
SYRE
+617.2%

Price return comparison

Growth of $10,000, price only

SNDX $6,034 · SYRE $71,724

Split-adjusted closes only. Distributions are excluded, which understates the return of any fund or stock that pays them.

Compare SNDX and SYRE against another ticker

Open a multi-ticker workspace without changing this focused pair page.

Basic: 2 symbols·Explorer: 3 symbols·Pro and Premium: 5 symbols·Your limit: 2

AIQ Factor Divergence

Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.

SNDX advantage
0
SYRE advantage
  • Momentum14 vs 81
    SYRE +67
  • Value64 vs 44
    SNDX +20
  • Risk Resilience37 vs 53
    SYRE +16
  • Quality66 vs 61
    SNDX +5

3 of 6 evidence groups favor SYRE. SYRE’s edge is concentrated in momentum and risk resilience; SNDX keeps a meaningful value edge.

What changed since the last close

Latest scored session 2026-11-13, compared against the prior scored session 2026-11-12.

SNDX+1 AIQ

Largest factor move: Value +2

No signal started or stopped since the prior session; its 7 active signals are unchanged.

SYRE+2 AIQ

Largest factor move: Momentum +2

New signals

  • ADX Trend Weakening — neutral, trend, medium horizon
  • Low Volume Rally Warning — bearish, volume, short horizon (0.75x)

SYRE's lead widened by 1 AIQ point in the latest session.

Deeper signal detail for each name lives on its own signals page — SNDX and SYRE both carry a full feed there.

The central trade-off

SYRE (Spyre Therapeutics, Inc.): the stronger current systematic profile, led by momentum and risk resilience.

SNDX (Syndax Pharmaceuticals, Inc.): the counter-case, on value, quality, fundamentals — but at materially higher volatility, 113.3% against 59.5%.

The AIQ Score and Wall Street therefore point in different directions on this pair.

Which one fits your objective

The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.

Balanced

SYRE

SYRE on the overall AIQ Score, which weights Quality and Value most heavily.

Growth

SNDX

SNDX on combined revenue and EPS growth.

Value

SNDX

SNDX on the peer-relative Value factor, by 20 points.

Momentum

SYRE

SYRE on the Momentum factor, by 67 points.

Lower downside

SYRE

SYRE on Risk Resilience, by 16 points.

Analyst upside

SNDX

SNDX on implied upside to the consensus price target.

AIQ vs Wall Street

The model and the Street disagree here: AIQ favors SYRE, analyst targets favor SNDX. That disagreement is the most useful thing on this page.

MeasureSNDXSYRENote
Implied upside to target+288.9%+18.1%SNDX has more room
Target dispersion+27.2%+11.4%Lower is tighter analyst agreement
ConsensusBuyBuyContext, not a primary driver
Analysts covering1218Higher coverage generally improves confidence

The two are measuring different things. The AIQ Score reads current fundamentals, valuation, trend and risk; analyst targets price forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something already priced in — it is worth resolving before acting on either.

Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.

AIQ Agreement Matrix

3 of 6 covered evidence groups favor SYRE. A wide gap backed by one group is a weaker case than a narrow gap backed by five.

Evidence groupFavorsReading
AIQ ScoreSYRE43 vs 64
FundamentalsSNDXTTM ROE 287.7% vs -9.1%; gross margin 93.7% vs 50%; operating margin -61.7% vs -276.5%
ValuationSNDXValue 64 vs 44
TechnicalsSYREPrice vs 50-day -38.1% vs 13.7%; vs 200-day -52.1% vs 35.7%
Risk ResilienceSYRERisk Resilience 37 vs 53
Analyst expectationsSNDXTarget upside 288.9% vs 18.1%

✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of SNDX and SYRE and are excluded from the count.

AIQ Decision Stability

Competitive

The two are close enough that your objective, not the score, should decide.

  • The AIQ gap is wide at 21 points. (supports the conclusion holding)
  • Only 3 of 6 covered evidence groups agree. (argues the conclusion is provisional)
  • The leader's advantage has been widening. (supports the conclusion holding)
  • The lead has been steady session to session. (supports the conclusion holding)
  • The leader is throwing conflicting signals. (argues the conclusion is provisional)

Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on SYRE.

How the comparison changed

120 daily snapshots · May 27 – Nov 13

SYRE lead: Strengthening — the AIQ differential moved from 14 to 21 points over 30 sessions.

May 27SNDX leads above the line · SYRE leads belowNov 13
Today
SYRE +21
43 vs 64
7 sessions ago
SYRE +18
44 vs 62
30 sessions ago
SYRE +14
43 vs 57
90 sessions ago
SYRE +16
53 vs 69

The lead has not changed hands in this window.

AIQ Signal Divergence

Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.

SNDXConflicted

1 bullish / 4 bearish / 2 neutral, conflicted

Only SNDX

  • Death Cross Active — bearish, trend, long horizon (29.12%)
  • 52-Week Low Proximity — bearish, risk_regime, long horizon (0.0%)
  • ADX Trend Strengthening — neutral, trend, medium horizon
  • Downtrend Structure Active — bearish, trend, long horizon
  • Keltner Channel Breakdown — bearish, volatility, short horizon
  • RSI Oversold — bullish, momentum, short horizon
SYREConflicted

4 bullish / 1 bearish / 2 neutral, conflicted

Only SYRE

  • Golden Cross Active — bullish, trend, long horizon (19.32%)
  • ADX Trend Weakening — neutral, trend, medium horizon
  • EMA Ribbon Expansion Bullish — bullish, trend, medium horizon
  • Low Volume Rally Warning — bearish, volume, short horizon (0.75x)
  • TRIX Bullish Signal — bullish, momentum, short horizon
  • Uptrend Structure Active — bullish, trend, long horizon

Both carry 1 more signal that do not separate them: ATR Expansion - Breakout Mode.

SYRE leads the comparison while carrying a conflicted signal state, which is one reason the stability rating is not higher.

Price vs model alignment

Whether the latest session's price move confirms what the model did over the same session, or contradicts it.

SNDXDivergence

Price is down while the AIQ Score moved up 1 points over the same session — price and model disagree (price -0.94%, AIQ +1 points).

SYREConfirmed strength

Price and the AIQ Score both moved up over the latest session (price +1.06%, AIQ +2 points).

What would flip this result

A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.

  1. 1SNDX closes the Momentum gap — currently 67 points behind, the largest single contributor to SYRE's edge.
  2. 2SNDX's Death Cross Active resolves — a bearish trend rule currently active against it.
  3. 3SYRE's conflicting signal state resolves bearish — it currently carries 4 bullish and 1 bearish rules at once.
  4. 4A market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.

The full evidence

Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.

Fundamentals

SNDX leads on balance
MetricSNDXSYRE
Revenue growth (YoY)14.4%0%
EPS growth (YoY)0%-161.1%
Gross margin93.7%50%
Operating margin-61.7%-276.5%
Return on equity (TTM)287.7%-9.1%
Debt to equity-34.310

Performance

SYRE leads 6 of 6 windows
MetricSNDXSYRE
1 week (5 sessions)-0.9%0.1%
1 month (20 sessions)-26.7%30.2%
3 months (63 sessions)-52.2%-0.6%
6 months (126 sessions)-53.3%38.8%
Year to date-55%217.5%
1 year (252 sessions)-43.7%343.9%

Technicals

SYRE has the stronger structure
MetricSNDXSYRE
RSI (14)26.259.4
ADX (14)47.717.9
Price vs 50-day-38.1%13.7%
Price vs 200-day-52.1%35.7%
Volatility (1M, annualized)113.3%59.5%

Risk

SYRE is the more resilient
MetricSNDXSYRE
Beta0.771.69
Sharpe ratio-0.762.57
Sortino ratio-0.974.62
Max drawdown-62.7%-27.8%
Current drawdown-62.4%-4.6%
Annualized volatility57.2%66.7%
Value at risk (95%)-4.5%-4.9%

Straight answers

Each answer is regenerated from the current snapshot, not written once and left to age.

Which is better, SNDX or SYRE?

On the Algovestiq AIQ Score, SYRE is the stronger of the two as of Nov 15, 2026, scoring 64 against SNDX's 43. The edge comes from momentum and risk resilience. SNDX is not without a case — it holds the better value profile, which matters more if that is the objective you are optimizing for. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.

Is SNDX or SYRE the better buy right now?

SYRE carries the stronger systematic profile as of Nov 15, 2026, and the comparison is rated Competitive — 3 of 6 covered evidence groups agree. A Competitive rating means the two are close enough that your objective, not the score, should decide.

Why does the AIQ Score favor SYRE over SNDX?

The composite weights Quality, Value, Momentum and Risk Resilience. SYRE leads Momentum by 67 points; SNDX leads Value by 20 points; SYRE leads Risk Resilience by 16 points. Where the two split, the factor with the larger weight carries the result.

Which has more analyst upside, SNDX or SYRE?

Analyst price targets imply +288.9% upside for SNDX and +18.1% for SYRE, so the Street currently favors SNDX. That points the opposite way to the AIQ Score, which favors SYRE. The two are measuring different things: the model reads current fundamentals, valuation, trend and risk; the Street is pricing forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something the analysts have already priced — it is the single most useful row on this page to investigate. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.

Which is better value, SNDX or SYRE?

SNDX is the better-valued of the two on the peer-relative Value factor. SNDX on the peer-relative Value factor, by 20 points. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.

Which has stronger growth, SNDX or SYRE?

SNDX on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.

Which has stronger momentum, SNDX or SYRE?

SYRE on the Momentum factor, by 67 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.

Which is riskier, SNDX or SYRE?

SYRE is the more resilient of the two, so the other name carries the higher downside risk. SYRE on Risk Resilience, by 16 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.

Is SNDX more profitable than SYRE?

SNDX leads on the comparable margin measures — gross margin 93.7% vs 50%; operating margin -61.7% vs -276.5%; ttm roe 287.7% vs -9.1%.

Is SYRE's lead over SNDX getting stronger or weaker?

SYRE lead: Strengthening — the AIQ differential moved from 14 to 21 points over 30 sessions. This is measured from 120 daily comparison snapshots between 2026-05-27 and 2026-11-13. The lead has not changed hands in that window.

What would change the SNDX vs SYRE verdict?

The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: SNDX closes the Momentum gap — currently 67 points behind, the largest single contributor to SYRE's edge; SNDX's Death Cross Active resolves — a bearish trend rule currently active against it; SYRE's conflicting signal state resolves bearish — it currently carries 4 bullish and 1 bearish rules at once; a market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.

What do the current signals say about SNDX and SYRE?

SNDX: 1 bullish / 4 bearish / 2 neutral, conflicted. SYRE: 4 bullish / 1 bearish / 2 neutral, conflicted. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on SNDX is Death Cross Active (bearish, long horizon). On SYRE it is Golden Cross Active (bullish, long horizon).

Compare SNDX and SYRE with others

Continue your research

This page answers which of the two. These answer the questions on either side of it.

How this comparison is scored

The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.

The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.

How to use side-by-side comparison →

This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.